newsfilter
← Latest News
GlobeNewswire·

Paratek Pharmaceuticals Announces Third Quarter 2022 Revenue of $30.2 Million

-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $25.5 Million from the Core Commercial Business, a 31% increase from $19.4 Million in Third Quarter 2021 -- Initiated Rabbit Pilot Efficacy Study for the